How is Thymosin Alpha 1 dosed?
Original dosing guidance
| Doses per vial | 3 to 10 |
|---|---|
| Route | Subcutaneous |
| Maintenance | Once a day for 3 to 10 days, repeated twice a year |
| Around exposure | Once daily for 3 to 10 days, before, during and after exposure to a cold, flu or virus |
Additional original dosing guidance
| Dose | 1 mg subcutaneously daily |
|---|---|
| Schedule | Five days on; two days off |
| Duration | For approximately eight weeks |
| Follow-up | Reassess |
What is Thymosin Alpha 1?
TA-1 is a 28-amino-acid peptide naturally produced in the thymus gland, first discovered in 1972.
The thymus is your central immune organ, and it shrinks with age, which is the rationale behind supplementing what it makes.
TA-1 is an immunomodulator rather than a stimulant. It plays a key role in the control of immunity, tolerance, and inflammation, regulating the immune response through a primary action on the innate immune system, and acting as an endogenous regulator of both inflammatory and adaptive responses.
The mechanism is straightforward: it stimulates production of cytotoxic T cells, working at the most fundamental levels of the immune system to activate signalling pathways and stimulate cytokines that coordinate other immune cells.
It has been tested across a wide variety of clinical trials since 1985, including 3000 patients ranging from 1 to 101 years old. That is a substantially deeper evidence base than most compounds in this library.
What is it used for?
Successfully used in hepatitis B and C, malignant melanoma, chronic fatigue, and certain cancers.
Clinical trials suggest it may be useful in cystic fibrosis, septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, tuberculosis, severe acute respiratory syndrome, and lung infections in critically ill patients.
COVID-19. One published study showed TA-1 reduced mortality in severe cases. Patients with CD8+ T cell counts below 400/μL or CD4+ below 650/μL gained the most benefit. TA-1 reverses T cell exhaustion and supports immune reconstitution by promoting thymus output during SARS-CoV-2 infection.
Reported benefits
- Significant repairing, restoring and healing properties
- Maintains normal antimicrobial activity
- Boosts mitochondrial function with increased ATP production
- Activates cell function and epigenetic gene expression
- Stimulates wound healing via angiogenesis, cell migration and stem cell differentiation
- Anti-inflammatory, decreasing inflammatory cytokines
- Increases nitric oxide levels
- Stimulates phagocytosis and autophagy
- Increases antioxidant and glutathione production
- Stimulates stem cell activity and proliferation
- Helps maintain healthy GI mucosa and blood-brain barrier permeability
- Reduces microglial activation from toxins, EMFs, infections and alcohol
- Binds and blocks neurotoxins, endotoxins and electromagnetic toxins
- Boosts natural killer cell function
- Breaks down biofilms and granulomas
- Reduces IL-6 induced immune and mitochondrial dysfunction
Side effects
Extremely safe, even showing fewer side effects than placebo in rare cases.
TA-1 modulates immune function, which means anyone with an autoimmune condition or taking immunosuppressive medication, including after a transplant, should involve their physician before starting. Modulation is not the same as suppression, but adding an immune-active compound to an existing immune-modifying regimen is a combination nobody has studied.
Do your own research.
Related: Thymosin Alpha 1 and depression
There is a separate discussion about TA-1 for depression tied to immune dysregulation or post-viral states, where inflammation rather than serotonin may be the driver.
Sourcing and quality
Peptides sold outside compounding pharmacies are labelled "Not For Human Consumption and For Research Use Only." Always ask for batch-specific third-party testing.
VIGEO Health does not sell injectable peptides. Email dawn@vigeohealth.net.
Test your foundations first
Immune function is one of the most mineral-dependent systems in the body. Zinc is required for T cell development, selenium for antioxidant enzymes and immune signalling, and both are commonly depleted.
Supporting immune signalling while the raw materials are short is the clearest case in this library for testing first.
See what the OligoScan measures
What this page does not tell you
- TA-1 is approved in some countries as Zadaxin, for hepatitis B and certain other indications, but research chemical material is not that product.
- The conditions listed are trial contexts, not claims about what this will do for you. Hepatitis, cancer and critical illness all require proper medical care.
- Autoimmune conditions and immunosuppressive medication warrant a physician's input.
- Not appropriate in pregnancy.
- Long-term safety data in healthy people is limited, despite the substantial clinical trial history in patient populations.
References and further reading
- Thymosin alpha 1: A comprehensive review of the literature
- Published research on TA-1 and mortality in severe COVID-19.
- VIGEO Health Medical Disclaimer
Related
Questions and Answers
Q: How is Thymosin Alpha 1 dosed? A: Once a day for 3 to 10 days, repeated twice a year. Alternatively, once daily for 3 to 10 days before, during and after exposure to a cold, flu or virus. It is a short-course compound used around a known risk window rather than taken continuously.
Q: What is Thymosin Alpha 1? A: A 28-amino-acid peptide naturally produced in the thymus gland, first discovered in 1972. It is an immunomodulator rather than a stimulant, regulating immunity, tolerance and inflammation through a primary action on the innate immune system. It has been tested in clinical trials since 1985 across 3000 patients aged 1 to 101.
Q: What is Thymosin Alpha 1 used for? A: It has been used in hepatitis B and C, malignant melanoma, chronic fatigue and certain cancers. Trials suggest possible use in cystic fibrosis, septic shock, acute respiratory distress syndrome, tuberculosis and lung infections in critically ill patients. One study showed reduced mortality in severe COVID-19.